Will a miotic agent or an agent that restores lens elasticity be more of an impactful pharmacologic therapy to treat presbyopia?

Click here to read the Cover Story to this Point/Counter.

One of these two pharmacologic approaches to the nonsurgical treatment of presbyopia includes PRX ophthalmic solution (Presbyopia Therapies). PRX eye drops are based on discoveries combining a proprietary vehicle with unique miotic combinations, without using pilocarpine. The drops are intended to induce strong miosis to create a significant pinhole effect with depth of field enhancement, without any associated accommodative distance blur.
In a recently completed randomized, double-masked, placebo-controlled phase 2b study, PRX

Full Story →